A study to assess the long-term safety outcomes in patients previously treated with RP1, RP2, or RP3
Research type
Research Study
Full title
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
IRAS ID
1012441
Contact name
Kari Jeschke
Contact email
Sponsor organisation
Replimune Inc.
Clinicaltrials.gov Identifier
Research summary
RP1, RP2, and RP3 are study medicines that could treat solid tumor cancers. They are special versions of the cold sore virus that is designed to target cancer cells and avoid infecting healthy cells. These study medicines also help the immune system to fight cancer. People with solid tumors have taken these medicines in clinical studies. In these studies, researchers learned about the side effects of these study medicines. In this study, researchers will look at the potential side effects of RP1, RP2, and RP3 that happened after people with solid tumor cancers finished being in a previous clinical study.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
25/LO/0746
Date of REC Opinion
28 Nov 2025
REC opinion
Further Information Favourable Opinion